| A596 |
Quisovalimab
Featured
|
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies. |
|
| A597 |
Certolizumab pegol
Featured
|
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). |
|
| A598 |
CDP-571
Featured
|
|
|
| A599 |
CMAB008
Featured
|
|
|
| A600 |
Epitomics patent anti-TNFα
Featured
|
|
|
| A601 |
ESBA-105
Featured
|
|
|
| A602 |
Anti-TNFSF2/TNFa Antibody (hMAK195)
Featured
|
|
|
| A603 |
Oxelumab
Featured
|
Oxelumab (R 4930) is a human monoclonal antibody against the OX40 ligand (OX40L). Oxelumab can be used for the research of asthma. |
|
| A604 |
Amlitelimab
Featured
|
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis. |
|
| A605 |
Ruplizumab
Featured
|
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research. |
|
| A606 |
Dapirolizumab
Featured
|
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus. |
|
| A607 |
Vorsetuzumab
Featured
|
Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma. |
|
| A608 |
Cusatuzumab
Featured
|
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML). |
|
| A609 |
Abbvie patent anti-TNFSF9
Featured
|
|
|
| A610 |
Naptumomab
Featured
|
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma. |
|
| DC67111 |
18:1 PEG2000 PE
Featured
|
18:1 PEG2000 PE (18:1 PEG-PE) is a polyethyleneglycol/phosphatidyl-ethanolamine conjugate. 18:1 PEG2000 PE can be used for drug delivery. |
|
| DC67112 |
DPPE-PEG2000
Featured
|
DPPE-PEG2000 (16:0 PEG2000 PE) is a PEG-modified lipids. 16:0 PEG2000 PE can reduce the nonspecific adsorption of protein and prolong circulation time in vivo. |
|
| DC67113 |
DPPE-DBCO
Featured
|
|
|
| A611 |
ASN004
Featured
|
|
|
| A612 |
Anti-TPBG Antibody (PF-06263507)
Featured
|
|
|
| A613 |
Wyeth patent anti-5T4
Featured
|
|
|
| A614 |
Genentech patent anti-Tryptase Beta 1
Featured
|
|
|
| A615 |
PY159
Featured
|
|
|
| A616 |
PY314
Featured
|
|
|
| A617 |
GBR-900
Featured
|
|
|
| A618 |
Rinat patent anti-TrkB
Featured
|
|
|
| A620 |
Sacituzumab
Featured
|
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer. |
|
| A621 |
Flanvotumab
Featured
|
Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance. |
|
| A622 |
Anti-TSHR Antibody (K1-70)
Featured
|
|
|
| A623 |
Schering patent anti-TSLP
Featured
|
|
|
